Eszopiclone + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Obstructive Sleep Apnea Syndrome
Conditions
Obstructive Sleep Apnea Syndrome
Trial Timeline
Aug 1, 2003 → Jan 1, 2004
NCT ID
NCT00685269About Eszopiclone + Placebo
Eszopiclone + Placebo is a phase 2 stage product being developed by Sumitomo Pharma for Obstructive Sleep Apnea Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00685269. Target conditions include Obstructive Sleep Apnea Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01102270 | Phase 1 | Completed |
| NCT00645944 | Pre-clinical | Completed |
| NCT00826111 | Approved | Completed |
| NCT00414037 | Approved | Terminated |
| NCT00386334 | Approved | Completed |
| NCT00833547 | Pre-clinical | Completed |
| NCT00392041 | Approved | Completed |
| NCT00365976 | Approved | Completed |
| NCT00555750 | Pre-clinical | Completed |
| NCT00374192 | Pre-clinical | Completed |
| NCT00368056 | Phase 3 | Completed |
| NCT00368160 | Phase 1 | Completed |
| NCT00367965 | Phase 3 | Completed |
| NCT00366093 | Phase 3 | Completed |
| NCT00352144 | Phase 3 | Completed |
| NCT00685269 | Phase 2 | Completed |
Competing Products
20 competing products in Obstructive Sleep Apnea Syndrome